Answers are grounded in this paper and cite their sources.
CADET trials demonstrate Candesartan's efficacy in reducing depressive symptoms in depression, indicating potential for clinical use as adjunctive medication.
The CADET Trials examine the efficacy of candesartan in reducing depressive symptoms in both unipolar and bipolar depression, and whether its effects are mediated through the renin-angiotensin system. Candesartan is affordable, accessible, and well-tolerated. If effective, it could quickly be adopted into clinical practice as a new adjunctive medication for the treatment of these disorders.
No takes yet. Share an insight, caveat, or question.
Ashton et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: